Applied Dna Sciences Inc (APDN) concluded trading on Wednesday at a closing price of $0.06, with 36.35 million shares of worth about $2.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -95.43% during that period and on March 12, 2025 the price saw a loss of about -56.80%. Currently the company’s common shares owned by public are about 54.11M shares, out of which, 51.42M shares are available for trading.
Stock saw a price change of -50.51% in past 5 days and over the past one month there was a price change of -62.71%. Year-to-date (YTD), APDN shares are showing a performance of -68.87% which decreased to -99.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.12 but also hit the highest price of $11.76 during that period. The average intraday trading volume for Applied Dna Sciences Inc shares is 4.25 million. The stock is currently trading -56.49% below its 20-day simple moving average (SMA20), while that difference is down -63.24% for SMA50 and it goes to -87.13% lower than SMA200.
Applied Dna Sciences Inc (NASDAQ: APDN) currently have 54.11M outstanding shares and institutions hold larger chunk of about 39.58% of that.
The stock has a current market capitalization of $3.50M and its 3Y-monthly beta is at 0.43. It has posted earnings per share of -$5.72 in the same period. It has Quick Ratio of 4.53 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APDN, volatility over the week remained 22.84% while standing at 10.31% over the month.
Analysts are in expectations that Applied Dna Sciences Inc (APDN) stock would likely to be making an EPS of -0.06 in the current quarter, while forecast for next quarter EPS is -0.05 and it is -0.11 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.06 which is -0.06 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -5.01 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 73.63% while it is estimated to increase by 77.08% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on February 12, 2021 offering a Buy rating for the stock and assigned a target price of $24 to it. Coverage by H.C. Wainwright stated Applied Dna Sciences Inc (APDN) stock as a Buy in their note to investors on January 14, 2021, suggesting a price target of $14 for the stock. On December 18, 2020, H.C. Wainwright Reiterated their recommendations, while on July 20, 2020, H.C. Wainwright Reiterated their ratings for the stock with a price target of $22. Stock get a Buy rating from H.C. Wainwright on July 02, 2020.
